PL3458610T3 - Leczenie raka piersi w oparciu o status c-MAF - Google Patents
Leczenie raka piersi w oparciu o status c-MAFInfo
- Publication number
- PL3458610T3 PL3458610T3 PL17729924T PL17729924T PL3458610T3 PL 3458610 T3 PL3458610 T3 PL 3458610T3 PL 17729924 T PL17729924 T PL 17729924T PL 17729924 T PL17729924 T PL 17729924T PL 3458610 T3 PL3458610 T3 PL 3458610T3
- Authority
- PL
- Poland
- Prior art keywords
- breast cancer
- therapeutic treatment
- cancer based
- maf status
- maf
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 102000007987 Proto-Oncogene Proteins c-maf Human genes 0.000 title 1
- 108010089507 Proto-Oncogene Proteins c-maf Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341333P | 2016-05-25 | 2016-05-25 | |
| US201662344836P | 2016-06-02 | 2016-06-02 | |
| PCT/IB2017/053094 WO2017203468A1 (en) | 2016-05-25 | 2017-05-25 | Therapeutic treatment of breast cancer based on c-maf status |
| EP17729924.5A EP3458610B1 (en) | 2016-05-25 | 2017-05-25 | Therapeutic treatment of breast cancer based on c-maf status |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3458610T3 true PL3458610T3 (pl) | 2021-11-22 |
Family
ID=59055237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17729924T PL3458610T3 (pl) | 2016-05-25 | 2017-05-25 | Leczenie raka piersi w oparciu o status c-MAF |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11596642B2 (pl) |
| EP (2) | EP3458610B1 (pl) |
| JP (3) | JP7032329B2 (pl) |
| KR (2) | KR102571924B1 (pl) |
| CN (2) | CN117230193A (pl) |
| AU (1) | AU2017271385B2 (pl) |
| CA (1) | CA3025264A1 (pl) |
| DK (2) | DK3458610T3 (pl) |
| ES (2) | ES2877757T3 (pl) |
| HR (1) | HRP20210921T1 (pl) |
| LT (1) | LT3458610T (pl) |
| MX (1) | MX2018014279A (pl) |
| PL (1) | PL3458610T3 (pl) |
| PT (1) | PT3458610T (pl) |
| WO (1) | WO2017203468A1 (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011311452B2 (en) | 2010-10-06 | 2016-09-01 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| CA2875918A1 (en) | 2012-06-06 | 2013-12-12 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| HK1213946A1 (zh) | 2012-10-12 | 2016-07-15 | Inbiomotion S.L. | 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法 |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| EP2975138A2 (en) | 2013-03-15 | 2016-01-20 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Method for the diagnosis, prognosis and treatment of cancer metastasis |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| WO2017203468A1 (en) | 2016-05-25 | 2017-11-30 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| AU2018372762B2 (en) | 2017-11-22 | 2025-08-21 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| KR102191049B1 (ko) | 2019-02-22 | 2020-12-15 | 엘지전자 주식회사 | 워터 디스펜싱 장치 |
| US20220195059A1 (en) * | 2019-04-30 | 2022-06-23 | Instituto de Medicina Molecular João Lobo Antunes | Rank Pathway Inhibitors in Combination with CDK Inhibitors |
| JP7509400B2 (ja) * | 2020-02-18 | 2024-07-02 | 国立研究開発法人量子科学技術研究開発機構 | 投与施設ユニット |
| KR20250030194A (ko) | 2023-08-24 | 2025-03-05 | 코웨이 주식회사 | 출수 장치 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE4013632A1 (de) | 1990-04-27 | 1991-10-31 | Max Planck Gesellschaft | Liposomen mit positiver ueberschussladung |
| EP0946725B1 (en) | 1996-12-23 | 2011-01-26 | Immunex Corporation | Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| EA200100972A1 (ru) | 1999-03-15 | 2002-02-28 | Аксис Фармасьютикалз, Инк. | Новые соединения и композиции как ингибиторы протеаз |
| AU779855B2 (en) | 2000-01-06 | 2005-02-17 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as protease inhibitors |
| PL222211B1 (pl) | 2001-06-26 | 2016-07-29 | Amgen Fremont Inc | Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| KR100485271B1 (ko) | 2002-01-16 | 2005-04-27 | 메타볼랩(주) | 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물 |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE10235624A1 (de) | 2002-08-02 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| EP1668354A2 (en) | 2003-09-24 | 2006-06-14 | Oncotherapy Science, Inc. | Method of diagnosing breast cancer |
| AU2003286499A1 (en) | 2003-10-17 | 2004-06-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| WO2005060722A2 (en) | 2003-12-18 | 2005-07-07 | President And Fellows Of Hardvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| JP2007527247A (ja) | 2004-03-05 | 2007-09-27 | ロゼッタ インファーマティクス エルエルシー | 臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類 |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| EP3211086B1 (en) | 2005-09-20 | 2021-06-09 | Menarini Silicon Biosystems S.p.A. | Methods and composition to generate unique sequence dna probes, labeling of dna probes and the use of these probes |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| US20080219996A1 (en) | 2005-09-26 | 2008-09-11 | Thea Kalebic | Molecular Markers Associated with Bone Metastasis |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| NZ581097A (en) | 2007-05-24 | 2012-03-30 | Ablynx Nv | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| WO2008145125A1 (en) | 2007-05-31 | 2008-12-04 | Dako Denmark A/S | Methods for utilizing esr copy number changes in breast cancer treatments and prognoses |
| NZ562237A (en) | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| US20110123617A1 (en) | 2007-10-18 | 2011-05-26 | University Health Network | Clioquinol for the treatment of hematological malignancies |
| US20110130296A1 (en) | 2008-03-14 | 2011-06-02 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
| WO2009146546A1 (en) | 2008-06-06 | 2009-12-10 | University Health Network | 8-hydroxyquinoline derivatives for the treatment of hematological malignancies |
| ES2338843B1 (es) | 2008-07-02 | 2011-01-24 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Huella genomica de cancer de mama. |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| SG176073A1 (en) | 2009-05-29 | 2011-12-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| WO2011017687A1 (en) | 2009-08-06 | 2011-02-10 | Ray Partha S | Diagnosis of primary and metastatic basal-like breast cancer and other cancer types |
| AU2011311452B2 (en) * | 2010-10-06 | 2016-09-01 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| CA2826657A1 (en) | 2011-02-04 | 2012-08-09 | Bioarray Therapeutics, Inc. | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment |
| EP2685988A4 (en) | 2011-03-15 | 2014-08-20 | Univ North Carolina | Methods of treating breast cancer with anthracycline therapy |
| EP2780469A1 (en) | 2011-11-18 | 2014-09-24 | Vanderbilt University | Markers of triple-negative breast cancer and uses thereof |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| CA2875918A1 (en) | 2012-06-06 | 2013-12-12 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| HK1213946A1 (zh) * | 2012-10-12 | 2016-07-15 | Inbiomotion S.L. | 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法 |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| AU2014229505B2 (en) | 2013-03-15 | 2020-02-27 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| EP2975138A2 (en) | 2013-03-15 | 2016-01-20 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Method for the diagnosis, prognosis and treatment of cancer metastasis |
| WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
| ES2727904T3 (es) | 2013-10-09 | 2019-10-21 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el pronóstico y tratamiento de cáncer metastatizante del hueso que se origina a partir de cáncer de mama |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| WO2017203468A1 (en) | 2016-05-25 | 2017-11-30 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| EP3296431A1 (en) | 2016-09-15 | 2018-03-21 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Method of synthesis of an electrode for use as a catalyst of oxygen evolution reaction |
| AU2018372762B2 (en) | 2017-11-22 | 2025-08-21 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
-
2017
- 2017-05-25 WO PCT/IB2017/053094 patent/WO2017203468A1/en not_active Ceased
- 2017-05-25 PT PT177299245T patent/PT3458610T/pt unknown
- 2017-05-25 EP EP17729924.5A patent/EP3458610B1/en active Active
- 2017-05-25 ES ES17729924T patent/ES2877757T3/es active Active
- 2017-05-25 LT LTEP17729924.5T patent/LT3458610T/lt unknown
- 2017-05-25 DK DK17729924.5T patent/DK3458610T3/da active
- 2017-05-25 PL PL17729924T patent/PL3458610T3/pl unknown
- 2017-05-25 EP EP21172098.2A patent/EP3901283B1/en active Active
- 2017-05-25 CN CN202311196940.8A patent/CN117230193A/zh active Pending
- 2017-05-25 JP JP2018561228A patent/JP7032329B2/ja active Active
- 2017-05-25 DK DK21172098.2T patent/DK3901283T3/da active
- 2017-05-25 AU AU2017271385A patent/AU2017271385B2/en active Active
- 2017-05-25 ES ES21172098T patent/ES3043607T3/es active Active
- 2017-05-25 US US16/303,945 patent/US11596642B2/en active Active
- 2017-05-25 KR KR1020187037303A patent/KR102571924B1/ko active Active
- 2017-05-25 CA CA3025264A patent/CA3025264A1/en active Pending
- 2017-05-25 KR KR1020237028682A patent/KR102867720B1/ko active Active
- 2017-05-25 CN CN201780042410.4A patent/CN109790582B/zh active Active
- 2017-05-25 HR HRP20210921TT patent/HRP20210921T1/hr unknown
- 2017-05-25 MX MX2018014279A patent/MX2018014279A/es unknown
-
2022
- 2022-02-24 JP JP2022026587A patent/JP2022060489A/ja not_active Withdrawn
-
2023
- 2023-02-15 US US18/169,537 patent/US20230381209A1/en active Pending
-
2024
- 2024-10-18 JP JP2024184425A patent/JP2025003539A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3458610B1 (en) | 2021-05-05 |
| BR112018074076A2 (pt) | 2019-03-06 |
| KR102571924B1 (ko) | 2023-08-28 |
| JP2019523641A (ja) | 2019-08-29 |
| PT3458610T (pt) | 2021-06-29 |
| JP7032329B2 (ja) | 2022-03-08 |
| LT3458610T (lt) | 2021-08-10 |
| JP2022060489A (ja) | 2022-04-14 |
| DK3901283T3 (da) | 2025-09-15 |
| US20190269707A1 (en) | 2019-09-05 |
| AU2017271385B2 (en) | 2023-10-05 |
| ES3043607T3 (en) | 2025-11-25 |
| AU2017271385A1 (en) | 2019-01-03 |
| KR20190021252A (ko) | 2019-03-05 |
| KR102867720B1 (ko) | 2025-10-01 |
| EP3901283A1 (en) | 2021-10-27 |
| CN117230193A (zh) | 2023-12-15 |
| US11596642B2 (en) | 2023-03-07 |
| US20230381209A1 (en) | 2023-11-30 |
| MX2018014279A (es) | 2019-07-08 |
| ES2877757T3 (es) | 2021-11-17 |
| CA3025264A1 (en) | 2017-11-30 |
| DK3458610T3 (da) | 2021-06-07 |
| EP3901283B1 (en) | 2025-08-06 |
| CN109790582B (zh) | 2023-10-03 |
| JP2025003539A (ja) | 2025-01-09 |
| WO2017203468A1 (en) | 2017-11-30 |
| CN109790582A (zh) | 2019-05-21 |
| HRP20210921T1 (hr) | 2021-09-03 |
| EP3458610A1 (en) | 2019-03-27 |
| KR20230128144A (ko) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3458610T3 (pl) | Leczenie raka piersi w oparciu o status c-MAF | |
| LT3474841T (lt) | Ar+ krūties vėžio gydymo būdai | |
| ZA201902454B (en) | Lasofoxifene treatment of er+ breast cancer | |
| SMT202000053T1 (it) | Trattamento combinato del cancro | |
| IL265697A (en) | Prostate cancer treatment | |
| IL266324A (en) | Treatment of her2-positive breast cancer | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| IL247940B (en) | Treatment of cancer damaged by 1brca or resistant cancers | |
| ZA201801022B (en) | Syd985 treatment of t-dm1 refractory cancer patients | |
| IL274748A (en) | Improved cancer treatment | |
| IL252639A0 (en) | Breast cancer treatment using taxane | |
| HK40098565A (zh) | 基於c-maf状态的乳腺癌治疗性治疗 | |
| HK40039177A (en) | Therapeutic treatment of breast cancer based on c-maf | |
| GB201718806D0 (en) | Breast cancer treatment | |
| GB201622214D0 (en) | treatment of cancer | |
| GB201704287D0 (en) | Treatment of cancer | |
| GB201703857D0 (en) | Treatment of cancer | |
| GB201702565D0 (en) | Treatment of cancer | |
| GB201604621D0 (en) | Treatment of cancer | |
| GB201604293D0 (en) | Treatment of cancer | |
| GB201717004D0 (en) | Methods of cancer therapy | |
| GB201702139D0 (en) | Methods of cancer treatment | |
| GB201711769D0 (en) | Methods of cancer therapy | |
| GB201703655D0 (en) | Lasofoxifene Treatment of breast cancer | |
| GB201704474D0 (en) | Combination therapy for treatment of cancer |